These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3526129)

  • 21. Gemfibrozil--a new lipid lowering agent.
    Nash DT
    J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of 3-glucosaminoglycan sulfate on hemorheologic parameters in hyperlipidemic peripheral vascular disease (PVD) patients: a preliminary double-blind crossover study.
    Ciuffetti G; Mercuri M; Susta A; Lupattelli G; Pasqualini L; Lombardini R; Mannarino E
    Angiology; 1989 Apr; 40(4 Pt 1):255-9. PubMed ID: 2705632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sulodexide treatment approach in patients with atherosclerotic vascular disease with various localizations].
    Capone-Braga M; Tellini L; Boncompagni L; Bettoni M; Burali A; Bensi A
    Clin Ter; 1987 Jan; 120(1):25-31. PubMed ID: 2973852
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness of short-term sulodexide treatment on peripheral vascular disease clinical manifestations.
    Caramelli L; Mirchioni R; Carini A
    Riv Eur Sci Med Farmacol; 1988 Feb; 10(1):55-8. PubMed ID: 3079198
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
    Bartnikowska E; Michajlik A; Wegrzyn B
    Pol Tyg Lek; 1983 Sep; 38(39):1219-21. PubMed ID: 6371736
    [No Abstract]   [Full Text] [Related]  

  • 26. Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use.
    Crepaldi G; Fellin R; Calabrò A; Rossi A; Ventura A; Mannarino E; Senin U; Ciuffetti G; Descovich GC; Gaddi A
    Atherosclerosis; 1990 Apr; 81(3):233-43. PubMed ID: 2190565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of polyenylphosphatidylcholine (PPC) on serum lipids in patients with hyperlipoproteinemia. A double-blind study].
    Horsch AK; Majolk I; Heuck CC; Göpfert E
    Vasa; 1986; 15(3):251-5. PubMed ID: 3532609
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
    Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
    Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
    [No Abstract]   [Full Text] [Related]  

  • 32. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of low dose omega-3-fatty acids on blood pressure, blood lipids and blood fluidity in patients with hyperlipoproteinemia].
    Staedt U; Kirschstein W; Simianer S; Kuhn C; Aufenanger J; Holm E
    Vasa Suppl; 1989; 27():253-4. PubMed ID: 2623506
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
    Madej A; Okopien B; Kowalski J; Zielinski M; Wysocki J; Szygula B; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of procetofen on lipoproteins and blood lipids in patients with hyperlipemia].
    Abaurre R; Vega J; Maneschi E; Bernabe H
    Medicina (B Aires); 1980; 40(6 Pt 2):896. PubMed ID: 7219169
    [No Abstract]   [Full Text] [Related]  

  • 37. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Przegl Lek; 1984; 41(9):581-6. PubMed ID: 6393227
    [No Abstract]   [Full Text] [Related]  

  • 38. [Localization of vessel lesions in arteriosclerosis and blood lipid composition].
    Lipovetskiĭ BM; Vinogradova TV
    Ter Arkh; 2002; 74(2):55-7. PubMed ID: 11899828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cross-over study of benfluorex and a hypolipemic agent in diet-resistant types IV and II b hyperlipemia (author's transl)].
    Graisely B; Cloarec M
    Sem Hop; 1980 Jun 18-25; 56(25-28):1221-5. PubMed ID: 6256875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.